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ABSTRACT
From January 2003 to December 2005, 5091 susceptibility test results from invasive isolates of Escherichia
coli, collected from blood cultures and cerebrospinal fluid routinely processed within 58 participating
laboratories, were investigated. These laboratories in turn serviced 64 hospitals in Algeria, Cyprus,
Egypt, Jordan, Lebanon, Malta, Morocco, Tunisia and Turkey. The median proportion of resistance to
third-generation cephalosporins for the duration of the project was 18.9% (interquartile range (IQR):
12.5–30.8%), and for fluoroquinolones 21.0% (IQR: 7.7–32.6%). A substantial proportion of strains
reported by laboratories in countries east of the Mediterranean exhibited evidence of multiresistance, the
highest proportion being from Egypt (31%). There is clearly a need for further investigation of potential
causes of the significant resistance identified, as well as for strengthening of national and international
surveillance initiatives within this region.‘
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INTRODUCTION
Serious infections, including septicaemia, caused
by resistant Gram-negative bacilli are associated
with increased mortality and longer hospital stay,
as compared with susceptible strains [1]. One of
the most common pathogens isolated from blood
cultures in this context is Escherichia coli [2]. This
organism also exhibits a potential for developing
antimicrobial resistance to various antibiotics
[3,4]. Significant levels of resistance against first-
line antibiotics such as ampicillin, trimethoprim
and co-trimoxazole have been noted for the past
decade [5]. Moreover, in recent years, reports of
increasing resistance to key therapeutic agents
such as fluoroquinolones (FQs) and third-gener-
ation cephalosporins (3GCs) have started to
emerge [6,7].
The epidemiology of resistance varies sub-
stantially on a global basis [5,8]. Even within
individual regions, major differences may be
present. In Europe, resistance proportions tend
to be highest among the southern countries,
especially those in the Mediterranean region [9].
However, information about the situation in the
non-European countries of this region has been
sparse. In addition to being few in number,
studies have often been unrelated, using differ-
ent methodologies, and, as a result, are difficult
to compare [10].
This lacuna has been addressed by theAntibiotic
Resistance Surveillance & Control in the Mediter-
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ranean Region (ARMed) project (http://
www.slh.gov.mt/armed) [11]. Over a 3-year per-
iod, this European Union-funded study has docu-
mented the prevalence of antibiotic resistance in
several key pathogens in nine southern and eastern
Mediterranean countries. This publication focuses
on the work undertaken to evaluate the status of
resistance in E. coli within participating laborato-
ries and hospitals in these countries.
MATERIALS AND METHODS
ARMed used a methodology identical to that utilized by the
European Antimicrobial Resistance Surveillance System
(EARSS) (http://www.rivm.nl/earss) [9]. This involved col-
lecting antimicrobial susceptibility test results for E. coli strains
routinely isolated from blood cultures and cerebrospinal fluid
within the 58 participating laboratories of the project. These
laboratories in turn serviced 64 hospitals in Algeria, Cyprus,
Egypt, Jordan, Lebanon, Malta, Morocco, Tunisia and Turkey.
The database included only the first isolate from any individ-
ual patient per year. The protocol for E. coli susceptibility
testing required, as a minimum, a sensitive, intermediate or
resistant interpretation of a b-lactam (amoxycillin or ampicil-
lin), an aminoglycoside (AG) (gentamicin and ⁄or tobramycin),
an FQ (ciprofloxacin and ⁄ or ofloxacin) and a 3GC (cefotaxime
or ceftriaxone and ⁄or ceftazidime).
ARMed also accepted antimicrobial susceptibility test data
for additional antibiotics if tests were routinely performed by
the participating laboratory. These optional antibiotics
included imipenem–meropenem, piperacillin, piperacillin
with tazobactam, amikacin, co-trimoxazole, tetracycline and
nalidixic acid. For the purposes of the study, an isolate
was defined as being multiresistant if it was concurrently
non-susceptible to AGs, FQs and 3GCs.
All antimicrobial susceptibility testing was performed by
the individual laboratories, who interpreted the results accord-
ing to their own guidelines, which in 70% of laboratories were
based on CLSI guidelines and breakpoints. The other labora-
tories followed the French guidelines of the Comite´ de
l’Antibiogramme de la Socie´te´ Franc¸aise de Microbiologie
(CA-SFM).
To gain an insight into the comparability of test results, two
external quality assessment (EQA) exercises were performed
in 2003 and 2004. These exercises were undertaken in collab-
oration with the EARSS, and utilized strains selected by the
EARSS EQA committee and distributed by United Kingdom
National External Quality Assessment Scheme (UK NEQAS)
[12]. In the 2003 EQA, one E. coli strain was distributed. There
was 100% concordance for species identification and high
concordance (‡88%) for the antibiotics tested. Two extended-
spectrum b-lactamase (ESBL)-producing E. coli strains were
included in the 2004 EQA exercise, including a CTX-M15
isolate. Resistance to 3GCs was tested using cefotaxime in 85%
of laboratories and using ceftriaxone in 50%; all laboratories
used at least one of these methods. A correct interpretation
was given by 95% of those centres using cefotaxime and by all
of the laboratories using ceftriaxone. The second strain of
E. coli in the 2004 EQA was a TEM-26 b-lactamase-producing
strain, which all laboratories correctly classified as ceftazi-
dime-susceptible. Under the EARSS methodology, ESBL
confirmatory testing was not obligatory, because laboratories
followed their own routine procedures. Therefore, resistance to
3GCs was utilized by ARMed as an indicator of ESBL
production.
A questionnaire was also sent to the hospitals serviced by
the testing laboratories in order to collect information on
blood-culturing practices. The blood-culturing rate was calcu-
lated from the questionnaire feedback as: total number of
blood cultures ⁄ total number of patient-days. Laboratories
were included in this part of the analysis only if all hospitals
within their catchment reported the respective bed information
data. Median and interquartile ranges were chosen to describe
resistance proportions, so as to avoid potential outlier effects
from individual laboratories or countries. Intracountry varia-
tions among the results obtained from the different participat-
ing laboratories were also considered. Country-specific trend
analysis was performed using the Cochrane–Armitage test.
Countries were obliged to report at least 20 isolates per year,
for all 3 years, to be included in the trend analysis. Most
analyses were performed in MEDCALC, version 9.2.1.0 (Medcalc
Software, Mariakerke, Belgium).
RESULTS
In total, 5091 E. coli isolates were reported to
ARMed for the 36-month study period (2003–
2005). Table 1 shows the proportions of resistance
reported by the laboratories in the participating
countries, both overall and for each individual
study year.
Aminopenicillin resistance
The highest proportions of resistance were found
for the aminopenicillins (median 68.2%; inter-
quartile range (IQR) 57.1–74.1%). In 2005, the
proportion of aminopenicillin-resistant E. coli
isolates varied between 49% (Malta) and 83%
(Lebanon). A significant trend of increased resis-
tance was observed for Turkey, from 68% to 75%
between 2003 and 2005.
Aminoglycoside resistance
The median AG resistance proportion for all
participating laboratories was 24.0% (IQR:17.8–
33.1%). By far the highest proportion of AG
resistance in 2005 was observed in Egypt (57%),
whereas the lowest proportion was reported from
Malta (7%). Between 2003 and 2005, a significant
increase was observed in Morocco, from 12% to
33%, and a significant decrease in Malta, from
18% to 7%.
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Third-generation cephalosporin resistance
The largest variation in resistance levels, among
both countries and laboratories in the individual
countries, was seen for 3GCs. The median
proportion of 3GC resistance for the duration of
the project was 18.9% (IQR: 12.5–30.8%). A wide
range was evident at country level, between 1%
in Malta and 70% in Egypt in 2005. From 2003 to
2005, laboratories in Morocco and Turkey showed
a significant increase in 3GC resistance, from 7%
to 33% and from 26% to 31%, respectively; on the
other hand, a significant decrease was seen in
Tunisia, from 20% to 11%. With the exception of
Malta, at least one ARMed laboratory in each
participating country reported 3GC resistance
levels in excess of 20%, with this situation being
present in the majority of hospitals in Turkey,
Algeria, Jordan and, especially, Egypt, where all
laboratories, except one, reported 3GC resistance
proportions in excess of 30% (Fig. 1).
FQ resistance
Evidence of substantial FQ resistance was also
received from many of the participating hospitals.
The overall median proportion of FQ resistance
was 21.0% (IQR: 7.7–32.6%). In 2005, Algeria
reported only 2% FQ resistance in E. coli, and this
was followed by 15% in Tunisia. Resistance
proportions in excess of 40% were observed in
Lebanon (53%), Egypt (48%) and Turkey (44%).
During the study period, a significant trend of
increased resistance was observed in Egypt and
Turkey.
Multidrug resistance
The distribution of multiresistance in E. coli was
also examined, according to our definition. In
2005, multiresistance rates below 5% were found
in Algeria, Cyprus and Malta. Multiresistance
was highest in Egypt, where more than 30% of
isolates were simultaneously resistant to AGs,
FQs and 3GCs. The participating laboratories
from this country reported only 15.6% of E. coli
strains as being fully sensitive to the three
antimicrobial agents. Over the 3-year period,
a significant increase in multiresistance was
observed in Egypt, Jordan and Morocco, with a
decrease being evident in Tunisian laboratories.
Carbapenem (CP) resistance
Although CP testing was optional, this was
performed for 4645 isolates. Resistance to CPs
0.0% 
10.0% 
20.0% 
30.0% 
40.0% 
50.0% 
60.0% 
70.0% 
80.0% 
90.0% 
100.0% 
Individual laboratories
Overall country proportion
Algeria         Malta        Morocco     Tunisia Cyprus        Egypt         Jordan      Lebanon      Turkey 
South East 
Fig. 1. Proportions of Escherichia coli resistance to third-generation cephalosporins at individual laboratory and country
levels for the entire surveillance period (2003–2005), including only participating centres reporting at least ten E. coli
isolates for the entire surveillance period.
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was generally low, with all countries showing
resistance proportions lower than 5%, except for
Egypt (9%).
There was also an interesting geographical dif-
ference in the phenotypic resistance profiles
between the southern and the eastern Mediterra-
nean laboratories. More than 75% of E. coli
isolates from Algerian, Tunisian and Maltese
laboratories were fully susceptible to AGs, FQs,
3GCs and CPs. On the other hand, more than 30%
of isolates from Egypt, Lebanon and Turkey were
resistant to at least two of these second-line agents
(Fig. 2).
DISCUSSION
The ARMed study is the first pan-regional study
of this nature in the south and east of the
Mediterranean region, and the information gath-
ered during this study constitutes the largest
dataset on the epidemiology of E. coli collected in
this region. Nevertheless, it is apparent from
sporadic earlier publications that reference has
already been made to significant levels of resis-
tance in some countries in this region, particularly
in Egypt. El Kholy and colleagues reported
resistance levels of 48% to 3GCs and 18% to
ciprofloxacin in blood culture isolates of E. coli
from five hospitals in Cairo in the years 1999–2000
[13]. High rates of resistance to both 3GCs and
FQs were also described by Saied in Cairo
hospitals [14]. The ARMed finding of an IQR of
13.3–37.9% for resistance to ciprofloxacin corre-
lates well with the EARSS results for the southern
European countries of Spain, Italy and Portugal,
which identified proportions in excess of 25% [9].
This suggests that the whole of the Mediterranean
region may be a high-prevalence region for
FQ resistance in this important Gram-negative
pathogen.
On the other hand, non-susceptibility to 3GCs
in E. coli remains substantially low, on both a
global and a European basis. In fact, networks
studying global antimicrobial resistance epidemi-
ology (e.g. MYSTIC, SENTRY and SMART) have
reported rates of less than 5% in the majority of
participants and rates rarely higher than 10%
[15,16]. Similar results have also been reported by
the EARSS network, even from their southern
European participants [9]. Consequently, the
results obtained from ARMed hospitals clearly
indicate a substantially higher prevalence of resis-
tance in these participating centres. Resistance to
Fig. 2. Percentage frequency of resistance profiles per country for Escherichia coli isolates for the entire surveillance period
(2003–2005); to be included, isolates had to be tested for all of the following four antibiotic groups: fluoroquinolones,
aminoglycosides, third-generation cephalosporins and carbapenems.
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3GCs within Enterobacteriaceae is often synony-
mous with the production of ESBLs [7]. These
transferable, plasmid-encoded enzymes hydro-
lyze and inactivate all b-lactam antibiotics, with
the exception of cephamycins and CPs [17].
Furthermore bacteria producing these enzymes
are often also resistant to other antimicrobial
agents, including AGs and FQs [18]. Several
ESBL-producing clonal groups have been identi-
fied, but it would appear that CTX-M-15 may
predominate within many countries in the south-
ern and eastern Mediterranean region. In fact,
strains producing this enzyme have been identi-
fied as the predominant 3GC-resistant E. coli
strains in studies within Egypt [13], Tunisia
[19,20], Turkey [21] and Lebanon [22]. Isolates of
E. coli bearing the blaCTX-M-15 gene, from both
inpatient and community sources, have been
characterized by a high degree of multiresistance
[23]. They have also been identified as being of
epidemic potential [24].
The predominance of these E. coli clones could
explain the extremely high levels of multiresis-
tance found in the isolates from many of the
laboratories in this study, particularly those from
eastern Mediterranean countries. Considering
that only 1% of E. coli isolates from the European
SENTRY study showed resistance to more than
four major antibiotics [25], it is quite significant to
find that eastern Mediterranean centres reported
10% or more of their E. coli isolates to be
concurrently resistant to at least three important
antimicrobial classes, those normally reserved for
the treatment of serious life-threatening infections
in the hospital setting. Furthermore, the level
of multiresistance in the ARMed laboratories
appears to be significantly higher than that
identified by EARSS participants in the European
region of the Mediterranean, who (with the
exception of those from Israel) reported levels
lower than 5% in 2005 [9]. These multiresistant
strains are undoubtedly a reason for concern,
because of the difficulty in treating serious infec-
tions that would be caused by them. This applies
not only to the countries themselves, but also to
others in the region and further afield, as impor-
tation of multiresistant Gram-negative pathogens
via returning travellers or migrants to Western
countries is becoming an ever more common
occurrence [26].
In order to obtain a basic dataset, the ARMed
project adopted the well-established ‘sentinel’
method of identifying individual hospitals and
laboratories in the country and ⁄ or region [27].
Sentinel surveillance is especially useful in the
case of developing countries, where surveillance
infrastructure and the funds required are often
lacking. Concern has been raised that the quality
of routine data may be compromised because
susceptibility testing methods and interpretative
criteria may not be standardized; thus, many
Enterobacteriaceae would be only partially iden-
tified, and the panels of antimicrobial agents
tested could differ among laboratories [28]. In the
case of ARMed, it was ensured that all partici-
pating laboratories used a common methodology
and an identical basic set of antimicrobial panels.
Furthermore, the satisfactory results obtained
from the EQA exercise (albeit on a restricted set
of strains) can be viewed as an additional indica-
tor of satisfactory diagnostic quality in the par-
ticipating laboratories. Finally, the comprehensive
size of the database lends additional strength to
the conclusions reached. Nevertheless, several
shortcomings should be kept in mind. The
blood-culturing rate varied substantially from
country to country, being lowest in Egypt, where
the highest resistance levels were identified.
Although it is difficult to establish with certainty
the extent to which this could have influenced the
high resistance proportions, it stands to reason
that if blood cultures are taken mainly after
therapeutic failure (in accordance with the culture
in the country), this will create a bias for isolates
with reduced susceptibility. Furthermore, differ-
ences in hospital sample mix are inevitable in
studies that rely on routine data, especially in
some developing countries, where surveillance
infrastructure would be absent in smaller district
laboratories. Also, the proportion of the popula-
tion covered differed considerably among coun-
tries. A high catchment population was possible
in the smaller countries such as Malta and
Cyprus, allowing a high level of confidence in
the results obtained, but such a high percentage
was clearly not possible in the larger nations.
However, this does not impede the drawing of
relevant conclusions. For example, although the
population covered by the Turkish hospitals was
low, the spread of participating laboratories
across the whole of this country and the inclusion
of all hospital types provide sufficient confidence
that the results are reasonably indicative of the
situation in the whole of the country. On the
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other hand, extrapolation of results from a
single laboratory (as in Lebanon and Morocco)
to a whole country should be undertaken with
extreme caution.
A major advantage in the ARMed study was
the methodological requirement that only the first
patient isolate per year was included. Shannon
and French showed significant differences of up
to 10% when a 5-day limit for same-patient
duplicates was used, as compared with the 365-
day limit of ARMed [29]. In addition, the choice of
blood cultures and cerebrospinal fluids ensured
that only invasive, and therefore clinically rele-
vant, isolates were included. The same authors
showed an additional significant difference of
6–10% in their results if isolates from screening
specimens were excluded. As the EARSS protocol
was adhered to, no investigation of the molecular
biology of the multiresistant strains isolated was
undertaken. This would have given additional
information on linkages and clonal spread among
institutions and even countries, as well as possi-
bly identifying the types of ESBL present in the
region. This is undoubtedly a future priority in
light of the findings of this study.
In conclusion, ARMed data on the status of
antimicrobial resistance in E. coli within the
south-eastern Mediterranean region clearly sug-
gest that a substantial proportion of hospitals in
many of the countries in this region face some
of the highest rates of multiresistance recorded
in this species. This in turn has significant
therapeutic implications in the context of serious
infections caused by these pathogens, both
within and outside the region. In fact, the
importation of multiresistant organisms to Euro-
pean hospitals via patients arriving from coun-
tries within the Mediterranean region is well
documented [30], even resulting in subsequent
intra-institutional spread, with the potential for
an outbreak [31]. These findings call for further
investigation of potential drivers behind
resistance trends, as well as for strengthening
of both national and international initiatives
aimed at improving surveillance of antimicro-
bial resistance in the region.
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